Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
<!-- Name:DistributionId Value:8810770 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Biliary Tract Cancer
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with…
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated…
European Medicines Agency Grants Orphan Drug Designation to Cornerstone…
Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as…